Paper39031809
Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.
Wu Y and 11 others. Adv Sci (Weinh), 2024. Cited by 68 papers, by iCite.
Cite this record
ConductScience Library. Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases. Papers, record 39031809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39031809
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Delivery Systems | Major topic |
| Eye Diseases | Major topic |
| Humans | |
| Nanotechnology | |
| Posterior Eye Segment | |
| Animals | |
| Nanomedicine | |
| Nanostructures | |
| Diabetic Retinopathy |
Source PubMed
Grants12
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82271048 | National Nature Science Foundation of China | PubMed | ||
| 61905130 | National Nature Science Foundation of China | PubMed | ||
| 23ZR1409500 | Project of Shanghai Science and Technology | PubMed | ||
| 23XD1420500 | Project of Shanghai Science and Technology | PubMed | ||
| 23S11900200 | Project of Shanghai Science and Technology | PubMed | ||
| 22S11900200 | Project of Shanghai Science and Technology | PubMed | ||
| 2021318 | EYE & ENT Hospital of Fudan University High-level Talents Program | PubMed | ||
| yg2023-06 | Medical Engineering fund of Fudan University | PubMed | ||
| yg2023-206 | Medical Engineering fund of Fudan University | PubMed | ||
| 2018M640145 | Postdoctoral Science Foundation of China | PubMed | ||
| 2019T120106 | Postdoctoral Science Foundation of China | PubMed | ||
| Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; | PubMed |
Source PubMed
References193
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31884933 | Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective. | Recent Pat Drug Deliv Formul | 2019 | https://conductscience.org/library/papers/31884933 | PubMed |
| 2 | 19689343 | Nanocarriers in ocular drug delivery: an update review. | Curr Pharm Des | 2009 | https://conductscience.org/library/papers/19689343 | PubMed |
| 3 | 39031809 | Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/39031809 | PubMed |
| 4 | 34923749 | The blood-retina barrier in health and disease. | FEBS J | 2023 | https://conductscience.org/library/papers/34923749 | PubMed |
| 5 | 29452593 | A review on biosynthesis of silver nanoparticles and their biocidal properties. | J Nanobiotechnology | 2018 | https://conductscience.org/library/papers/29452593 | PubMed |
| 6 | 36871144 | MMP9-Responsive Graphene Oxide Quantum Dot-Based Nano-in-Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization. | Small | 2023 | https://conductscience.org/library/papers/36871144 | PubMed |
| 7 | 18275911 | Current and future ophthalmic drug delivery systems. A shift to the posterior segment. | Drug Discov Today | 2008 | https://conductscience.org/library/papers/18275911 | PubMed |
| 8 | 11276432 | Fibroblast growth factors. | Genome Biol | 2001 | https://conductscience.org/library/papers/11276432 | PubMed |
| 9 | 36461689 | Functional Carbon Quantum Dots for Ocular Imaging and Therapeutic Applications. | Small | 2023 | https://conductscience.org/library/papers/36461689 | PubMed |
| 10 | 23584393 | Extracellular vesicles: biology and emerging therapeutic opportunities. | Nat Rev Drug Discov | 2013 | https://conductscience.org/library/papers/23584393 | PubMed |
| 11 | 30849371 | VEGF in Signaling and Disease: Beyond Discovery and Development. | Cell | 2019 | https://conductscience.org/library/papers/30849371 | PubMed |
| 12 | 34527806 | Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy. | Adv Ther (Weinh) | 2021 | https://conductscience.org/library/papers/34527806 | PubMed |
| 13 | 21884302 | Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. | Pathol Int | 2011 | https://conductscience.org/library/papers/21884302 | PubMed |
| 14 | 30583149 | Mussel-inspired injectable hydrogel and its counterpart for actuating proliferation and neuronal differentiation of retinal progenitor cells. | Biomaterials | 2019 | https://conductscience.org/library/papers/30583149 | PubMed |
| 15 | 26709963 | Quantum dot as probe for disease diagnosis and monitoring. | Biotechnol J | 2016 | https://conductscience.org/library/papers/26709963 | PubMed |
| 16 | 29637733 | Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment. | J Biomed Mater Res A | 2018 | https://conductscience.org/library/papers/29637733 | PubMed |
| 17 | 30257317 | Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy. | Biomed Pharmacother | 2018 | https://conductscience.org/library/papers/30257317 | PubMed |
| 18 | 33669093 | Beneficial Effect of Tempol, a Membrane-Permeable Radical Scavenger, on Inflammation and Osteoarthritis in In Vitro Models. | Biomolecules | 2021 | https://conductscience.org/library/papers/33669093 | PubMed |
| 19 | 34041903 | Graphene Family Nanomaterials in Ocular Applications: Physicochemical Properties and Toxicity. | Chem Res Toxicol | 2021 | https://conductscience.org/library/papers/34041903 | PubMed |
| 20 | 30530176 | Pharmaceutical applications of chitosan. | Adv Colloid Interface Sci | 2019 | https://conductscience.org/library/papers/30530176 | PubMed |
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 68 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42898393 | Application of nanozyme-based drug delivery systems in the treatment of ROS-related ophthalmic diseases. | Int J Pharm X | 2026 | https://conductscience.org/library/papers/42898393 | PubMed |
| 42654098 | Hydrogel-Based Ocular Drug Delivery Systems: A Bibliometric and Visualization Analysis of Research Trends and Hotspots (1991-2025). | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42654098 | PubMed |
| 42640395 | Exosomes in the treatment of age-related ophthalmic diseases: an updated review. | Int Ophthalmol | 2026 | https://conductscience.org/library/papers/42640395 | PubMed |
| 42434121 | Nanomaterial-enabled delivery of plant-derived bioactive metabolites for diabetic retinopathy: from evidence appraisal to preclinical translation. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42434121 | PubMed |
| 42415853 | Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42415853 | PubMed |
| 42298628 | Dual-targeting VEGF and TNF-α with bispecific antibody eyedrops for synergistic treatment of uveitis. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42298628 | PubMed |
| 42278630 | Special Issue "Integrated Approaches, Molecular Mechanisms and Therapies in Ocular Surface Diseases". | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278630 | PubMed |
| 42195365 | Nanocarrier-Based Ocular Drug Delivery Systems for Retinal Diseases: Therapeutic Potential. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42195365 | PubMed |
| 42100289 | Relationship between choroidal thickness changes and macrophage polarization in high myopia. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42100289 | PubMed |
| 42090084 | Extracellular vesicles in ophthalmology: innovations in diagnosis, therapy, and drug delivery. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42090084 | PubMed |
| 42042291 | Advances and Challenges in Tissue Engineering: Biomaterials, Cellular Strategies, and Clinical Applications. | J Funct Biomater | 2026 | https://conductscience.org/library/papers/42042291 | PubMed |
| 42007156 | The impact of anti-vascular endothelial growth factor therapy on the activation status of retinal macrophages/microglia in patients with diabetic retinopathy and familial exudative vitreoretinopathy and its association with treatment response. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42007156 | PubMed |
| 41987176 | A sequential dual-drug delivery system for multi-target inhibition of subretinal fibrosis. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41987176 | PubMed |
| 41976211 | Engineering Strategies of Colloidal Drug Delivery Systems, a Rising Star in Ocular Neovascular Diseases. | Molecules | 2026 | https://conductscience.org/library/papers/41976211 | PubMed |
| 41939725 | Engineered small extracellular vesicles as bioactive materials: Integrating engineering strategies for cargo loading and targeted delivery systems. | Bioact Mater | 2026 | https://conductscience.org/library/papers/41939725 | PubMed |
| 41858590 | The Cross-Species Implantable ATP Battery Inspired by Photosynthesis for Application in Diseases. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41858590 | PubMed |
| 41677384 | Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41677384 | PubMed |
| 41660128 | ROS-responsive transmembrane peptide-antibody conjugate eyedrops for the non-invasive treatment of choroidoretinopathy. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/41660128 | PubMed |
| 41604030 | Nanotherapeutic potential in glaucoma associated ocular cancers. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41604030 | PubMed |
| 41549124 | Diabetes and its complications: molecular mechanisms, prevention and treatment. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/41549124 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39031809
GET https://conductscience.org/api/papers/v1/39031809/references?page=2